Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.
Treats metastatic non-small cell lung cancer (NSCLC). Sold as Iressa. Every FDA application for this active ingredient: 2 branded and 5 generic.
As of Nov 16, 2026, FDA lists 7 applications for Gefitinib (sold as Iressa), first approved May 5, 2003, with 0 new uses approved and 0 published complete response letters.
First approved: May 5, 2003
Applications: 7
New uses approved: 0
Complete response letters: 0
Medicare spending, 2025: $3.7M
First approved in the EU: Jun 24, 2009
Medicare Spending
CMS Part D and Part B, 2025, before manufacturer rebates; matched by generic name
IressaA drug with a revised indication for the treatment of unresectable advanced or recurrent non-small cell lung cancer in patients with EGFR gene mutation. · AstraZeneca K.K. · Nov 25, 2011
Clinical Trials
16 open or ongoing studies name this ingredient as an intervention, including as a comparator; newest first. See all
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient.Drugs@FDA